Pharmaron Beijing Co Ltd (300759) - Total Liabilities
Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) has total liabilities worth CN¥10.62 Billion CNY (≈ $1.55 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmaron Beijing Co Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Pharmaron Beijing Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Pharmaron Beijing Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Pharmaron Beijing Co Ltd Competitors by Total Liabilities
The table below lists competitors of Pharmaron Beijing Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥5.46 Billion |
|
UNIQA Insurance Group AG
VI:UQA
|
Austria | €25.46 Billion |
|
EPAM Systems Inc
NYSE:EPAM
|
USA | $1.27 Billion |
|
Associated Banc-Corp
NYSE:ASB
|
USA | $40.60 Billion |
|
Selective Insurance Group, Inc.
NASDAQ:SIGI
|
USA | $11.73 Billion |
|
Asia Commercial Bank
VN:ACB
|
Vietnam | ₫931.33 Trillion |
|
China National Software & Service Co Ltd
SHG:600536
|
China | CN¥4.74 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Pharmaron Beijing Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pharmaron Beijing Co Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmaron Beijing Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmaron Beijing Co Ltd (2014–2024)
The table below shows the annual total liabilities of Pharmaron Beijing Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥9.70 Billion ≈ $1.42 Billion |
-26.70% |
| 2023-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
+37.15% |
| 2022-12-31 | CN¥9.65 Billion ≈ $1.41 Billion |
+19.26% |
| 2021-12-31 | CN¥8.09 Billion ≈ $1.18 Billion |
+172.06% |
| 2020-12-31 | CN¥2.98 Billion ≈ $435.34 Million |
+41.87% |
| 2019-12-31 | CN¥2.10 Billion ≈ $306.86 Million |
-8.17% |
| 2018-12-31 | CN¥2.28 Billion ≈ $334.16 Million |
+19.63% |
| 2017-12-31 | CN¥1.91 Billion ≈ $279.33 Million |
+83.35% |
| 2016-12-31 | CN¥1.04 Billion ≈ $152.35 Million |
+3.48% |
| 2015-12-31 | CN¥1.01 Billion ≈ $147.23 Million |
+49.45% |
| 2014-12-31 | CN¥673.22 Million ≈ $98.51 Million |
-- |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more